Starpharma today released its annual report and financial results for the year ended 30 June 2010.

Cash reserves of $22.8 million are a result of prudent management of cash, successful capital raising and continuing partnering revenues, and interest received throughout the year.

Abstract: While much has been communicated about Starpharma's Vivagel product and its application as a microbicidal condom coating, the company was asked to present on the rapidly strengthening interest in the use of the company's dendrimers for the application of drug delivery.